MX2018000336A - Fluido terapeutico peritoneal. - Google Patents

Fluido terapeutico peritoneal.

Info

Publication number
MX2018000336A
MX2018000336A MX2018000336A MX2018000336A MX2018000336A MX 2018000336 A MX2018000336 A MX 2018000336A MX 2018000336 A MX2018000336 A MX 2018000336A MX 2018000336 A MX2018000336 A MX 2018000336A MX 2018000336 A MX2018000336 A MX 2018000336A
Authority
MX
Mexico
Prior art keywords
therapeutic fluid
peritoneal therapeutic
polyphenolic compound
peritoneal
metabolization
Prior art date
Application number
MX2018000336A
Other languages
English (en)
Inventor
Grentzmann Guido
Original Assignee
Opterion Health Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opterion Health Ag filed Critical Opterion Health Ag
Publication of MX2018000336A publication Critical patent/MX2018000336A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
    • A61M1/287—Dialysates therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0021—Special media to be introduced, removed or treated removed from and reintroduced into the body, e.g. after treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0413—Blood

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • External Artificial Organs (AREA)

Abstract

Fluido terapéutico peritoneal que comprende uno o más de un agente potenciador de la biocompatibilidad (BCA) que se selecciona del grupo que consiste en un compuesto polifenólico, un metabolito de un compuesto polifenólico que se obtiene por metabolización en el cuerpo humano o animal, una sal o un glucósido de un compuesto polifenólico.
MX2018000336A 2015-07-20 2016-07-19 Fluido terapeutico peritoneal. MX2018000336A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15177544.2A EP3120842A1 (en) 2015-07-20 2015-07-20 Peritoneal therapeutic fluid
PCT/EP2016/067186 WO2017013120A1 (en) 2015-07-20 2016-07-19 Peritoneal therapeutic fluid

Publications (1)

Publication Number Publication Date
MX2018000336A true MX2018000336A (es) 2018-05-22

Family

ID=53785450

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000336A MX2018000336A (es) 2015-07-20 2016-07-19 Fluido terapeutico peritoneal.

Country Status (23)

Country Link
US (2) US20180221303A1 (es)
EP (2) EP3120842A1 (es)
JP (1) JP6448847B2 (es)
KR (2) KR20180048577A (es)
CN (2) CN107921009B (es)
AU (1) AU2016296216B2 (es)
BR (1) BR112018001005B1 (es)
CA (1) CA2990532C (es)
CO (1) CO2018000236A2 (es)
CY (1) CY1124467T1 (es)
DK (1) DK3324951T3 (es)
ES (1) ES2880796T3 (es)
HK (1) HK1251176A1 (es)
HR (1) HRP20211319T1 (es)
HU (1) HUE055208T2 (es)
LT (1) LT3324951T (es)
MX (1) MX2018000336A (es)
PL (1) PL3324951T3 (es)
PT (1) PT3324951T (es)
RS (1) RS62142B1 (es)
RU (1) RU2718908C2 (es)
SI (1) SI3324951T1 (es)
WO (1) WO2017013120A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3381484A1 (en) * 2017-03-31 2018-10-03 Opterion Health AG Carbohydrate composition for dialysis
CN108310005A (zh) * 2018-04-18 2018-07-24 浙江天瑞药业有限公司 一种抗腹膜纤维化的腹膜透析液
EP3866922A1 (en) * 2018-10-16 2021-08-25 President and Fellows of Harvard College Sirt1 activating compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2155910C (en) * 1995-08-11 1999-12-14 George Wu Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis
IL147500A0 (en) * 1999-08-10 2002-08-14 Ml Lab Plc Method for delivery of therapeutic agents using a solution of dextrin
AU7879500A (en) * 1999-10-15 2001-04-30 Dow Global Technologies Inc. Dialysis solution including polyglycol osmotic agent
JP4882054B2 (ja) 2000-09-13 2012-02-22 独立行政法人科学技術振興機構 腹膜透析液およびその調製法
WO2003024391A2 (en) * 2001-08-16 2003-03-27 Mucosal Therapeutics, Inc. Treatment and prevention of mucositis in cancer patients
GB0200704D0 (en) * 2002-01-14 2002-02-27 Britannia Pharmaceuticals Ltd Use of phospholipids in peritoneal dialysis
ITRM20020562A1 (it) * 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
SE524530C2 (sv) * 2002-12-10 2004-08-24 Gambro Lundia Ab Metod för att framställa en medicinsk lösning för peritonealdialys där en lösning innehållandes ett eller flera acetylerade eller deacetylerade aminosocker värme- eller strålningssteriliseras med bestämda pH-värden och med bestämda viktsprocent för att undvika att cytotoxiska produkter bildas.
CA2546019A1 (en) * 2003-11-17 2005-06-02 Braintree Laboratories, Inc. Therapeutic peg solution concentrate
US7498341B2 (en) 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7384558B2 (en) 2004-07-26 2008-06-10 Baxter International Inc. Compositions capable of inhibiting reactive oxygen and carbonyl species
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
EP2322158B1 (en) 2005-10-26 2020-06-10 Kao Corporation Resveratrol and/or grape leaf extract for energy metabolism activation
ES2685094T3 (es) * 2007-07-31 2018-10-05 Elc Management Llc Composiciones cosméticas que contienen resveratrol
US20090035240A1 (en) * 2007-07-31 2009-02-05 Maes Daniel H Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent
CA2748344A1 (en) * 2008-11-26 2010-06-03 Lipoprotein Technologies, Inc. Enhanced bioactive formulations of resveratrol
BRPI1005154A2 (pt) * 2009-01-19 2018-02-06 Lycored Ltd "composição terapêutica, método para inibir ou reduzir a produção de íons superóxido, óxido nítrico (no), fator necrose tumoral alfa (tnf-alfa) e/ou prostaglandina e2 (pge2) em um indivíduo mamífero, métodos de tratamento e uso de uma combinação"
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
ES2365429B1 (es) * 2010-03-05 2012-09-06 Universidad De Castilla De La Mancha Solucion para dialisis peritoneal
EP2609918A1 (en) * 2011-12-27 2013-07-03 Zytoprotec GmbH Peritoneal dialysis fluid comprising a GSK-3 inhibitor
WO2013159188A1 (en) * 2012-04-24 2013-10-31 The University Of British Columbia Polymer-based dialysate
EP2695606A1 (en) * 2012-08-09 2014-02-12 ETH Zürich Liposome composition for peritoneal dialysis
ITRM20130135A1 (it) * 2013-03-06 2014-09-07 Michele Azzolini Nuovi derivati del resveratrolo.
CN103330715B (zh) * 2013-07-01 2015-09-02 华仁药业股份有限公司 一种抗腹膜纤维化的腹膜透析液

Also Published As

Publication number Publication date
PL3324951T3 (pl) 2021-12-13
HRP20211319T1 (hr) 2021-11-26
AU2016296216A1 (en) 2017-12-14
BR112018001005B1 (pt) 2023-11-28
BR112018001005A2 (pt) 2022-09-06
CN107921009B (zh) 2020-12-11
KR102266889B1 (ko) 2021-06-18
US20180221303A1 (en) 2018-08-09
HK1251176A1 (zh) 2019-01-25
KR20180048577A (ko) 2018-05-10
JP2018522894A (ja) 2018-08-16
JP6448847B2 (ja) 2019-01-09
CN107921009A (zh) 2018-04-17
RU2018106122A3 (es) 2019-10-10
ES2880796T3 (es) 2021-11-25
RS62142B1 (sr) 2021-08-31
DK3324951T3 (da) 2021-08-23
LT3324951T (lt) 2021-07-26
EP3324951B1 (en) 2021-05-26
AU2016296216B2 (en) 2019-05-02
RU2718908C2 (ru) 2020-04-15
CA2990532A1 (en) 2017-01-26
US20200022926A1 (en) 2020-01-23
WO2017013120A1 (en) 2017-01-26
EP3120842A1 (en) 2017-01-25
CY1124467T1 (el) 2022-07-22
HUE055208T2 (hu) 2021-11-29
US11160766B2 (en) 2021-11-02
SI3324951T1 (sl) 2021-09-30
RU2018106122A (ru) 2019-08-20
PT3324951T (pt) 2021-07-20
KR20190025759A (ko) 2019-03-11
CA2990532C (en) 2020-07-14
EP3324951A1 (en) 2018-05-30
CN110075307A (zh) 2019-08-02
CO2018000236A2 (es) 2018-06-12

Similar Documents

Publication Publication Date Title
HK1251546A1 (zh) S-氯胺酮的(s)-csa鹽、s-氯胺酮的(r)-csa鹽和用於製備s-氯胺酮的方法
IL272444A (en) Compounds, their salts and methods for treating diseases
EP3691549A4 (en) BLOOD STOPPER OR RESTRICTION CUFF
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
NZ732511A (en) Small molecule inhibitors of egfr and pi3k
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
IL254457B (en) A combination of a bactericide and a lysosomotropic alkaline agent for the treatment of bacterial infection
CY1124467T1 (el) Περιτοναϊκο θεραπευτικο υγρο
MX2020011099A (es) Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar.
PH12016501769A1 (en) Treatment of intrahepatic cholestatic diseases
EA033446B1 (ru) Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта
PH12018501709A1 (en) Naphthridinedione derivatives
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX2018014915A (es) Tratamiento de enfermedades colestasicas intrahepaticas.
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
IL270140B (en) A therapeutic agent for blood cancer
BR112017026003A2 (pt) ?agente de imagem de diagnóstico para metástase óssea precoce de câncer?
NZ717880A (en) Glucopyranosyl-substituted indole-urea derivatives and their use as sglt inhibitors
BR112018006055A2 (pt) implante médico trançado.
GEP20197007B (en) Therapeutic agent for frontal lobe dysfunction
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
WO2016025494A3 (en) Methods of monitoring adherence to quetiapine therapy
MX2019007490A (es) Composicion que contiene acido n-acetildiamino butirico.
PH12016502111A1 (en) Drug for treatment of tinnitus patients
TH172004B (th) องค์ประกอบ